Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates:18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial
| العنوان: | Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates:18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial |
|---|---|
| المؤلفون: | Lene Boesby, Claus Bistrup, Lykke Larsen, Isik somuncu Johansen, Christian Nielsen, Søren Schwartz Sørensen, Charlotte Sværke Jørgensen |
| المصدر: | Larsen, L, Bistrup, C, Sørensen, S S, Boesby, L, Jørgensen, C S, Nielsen, C & Johansen, I S 2022, ' Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates : 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial ', Vaccines, vol. 10, no. 7, 1091 . https://doi.org/10.3390/vaccines10071091 Vaccines; Volume 10; Issue 7; Pages: 1091 |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Pharmacology, Infectious Diseases, 13-valent pneumococcal conjugate vaccine, Drug Discovery, Immunology, Pharmacology (medical), kidney transplant recipient, 23-valent pneumococcal polysaccharide, immunogenicity |
| الوصف: | Background: Pneumococcal prime-boost vaccination is recommended for solid organ transplant recipients and candidates. The long-term durability of the antibody (AB) response is unknown. The same applies to a dose-dependent immune response. Methods: We studied the durability of the vaccine response after 18 months in kidney transplant recipients (KTRs) and patients on the kidney transplant waiting list (WLPs). Both groups received either a normal dose (ND) or a double dose (DD) of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine. The average pneumococcal AB geometric mean concentration (GMC) was evaluated. A level ≥ 1 mg/L was considered protective against invasive pneumococcal disease (IPD). Results: Sixty WLPs and 70 KTRs were included. The proportion of participants protected declined from 52% to 33% in WLPs and from 29% to 16% in KTRs, with the previously significant dose-effect in WLPs no longer present (40% DD vs. 27% ND; p = 0.273). Average pneumococcal AB GMCs remained significantly above baseline levels (all groups p ≤ 0.001). Drug-induced immunosuppression diminished the vaccine dose-effect. Conclusions: At follow-up, the pneumococcal prime-boost vaccination still provided significantly elevated average pneumococcal AB GMCs in both populations. Though the proportion of participants protected against IPD in WLP-DD and WLP-ND were statistically comparable, a DD may still be recommended for WLPs (EudraCT: 2016-004123-23). |
| وصف الملف: | application/pdf |
| اللغة: | English |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb84e4a40a4d100ef528dfbf1f86420 https://curis.ku.dk/ws/files/321822120/vaccines_10_01091_v2.pdf |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....8cb84e4a40a4d100ef528dfbf1f86420 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |